Profile Response Detail

Molecular Profile KRAS G13D
Therapy Pimasertib
Indication/Tumor Type colorectal cancer
Response Type decreased response
Create By tyin
Update By tyin

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
KRAS G13D colorectal cancer decreased response Pimasertib Preclinical - Cell culture Actionable In a preclinical study, colorectal cancer cells harboring KRAS G13D demonstrated decreased response to Pimasertib (MSC1936369B) in culture (PMID: 23629727). 23629727
PubMed Id Reference Title Details
(23629727) Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Full reference...